Pharmacyclics, Inc. (PCYC) Posts Q4 Loss of 22c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts PCYC Hot Sheet
Price: $261.25 --0%
Financial Fact:
Total revenues: 205.77M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Financial Fact:
Total revenues: 205.77M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Pharmacyclics, Inc. (NASDAQ: PCYC) reported Q4 EPS of ($0.22), $0.05 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $2.1 million versus the consensus estimate of $3.49 million.
For earnings history and earnings-related data on Pharmacyclics, Inc. (PCYC) click here.
For earnings history and earnings-related data on Pharmacyclics, Inc. (PCYC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- BioNTech and Bristol Myers Squibb report Phase 2 data for pumitamig in NSCLC
- Bristol Myers Squibb MS CAR T therapy data shows patients off DMTs
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
